Foresee Pharmaceuticals Co., Ltd.

Foresee Pharmaceuticals Co., Ltd. is a clinical-stage biopharmaceutical company specializing in the development and distribution of novel pharmaceuticals. Founded in 2013 and headquartered in Taipei, the company focuses on two principal technology platforms: Stabilized Injectable Formulation (SIF), which enables the creation of long-acting injectable therapies, and Rational Drug Design for innovative new chemical entities. Foresee’s diversified pipeline targets both high unmet medical needs and specialty markets, addressing conditions such as prostate cancer, breast cancer, asthma, respiratory syndromes, neurological diseases, and rare disorders like Fanconi anemia. The company’s flagship product, a ready-to-use leuprolide injection (CAMCEVI®), is approved for advanced prostate cancer and is expanding to other indications. With ongoing clinical trials and global commercial partnerships, Foresee Pharmaceuticals plays a vital role in advancing therapeutics within the health technology sector, particularly in specialty and generic drug manufacturing across Asia, North America, and Europe. The company’s commitment to scientific innovation and unmet patient needs distinguishes its market presence and drives its continuous research and development initiatives.